Singapore monetary authority penalizes 9 banks, institutions for 2023 money laundering case
The case involved more than S$3 billion ($2.2 billion) in illicit assets seized after 10 foreigners were busted in a series of simultaneous raids in August 2023.
The total penalty is just shy of the S$29.1 million in financial penalties meted out to eight banks in a case involving Malaysia's 1MDB in 2017.
The banks involved — Credit Suisse, UOB, UBS, Citibank, Julius Baer and LGT Bank — were each penalised between S$1million and S$5.8 million.
Brokerage firm UOB Kay Hian, asset management firm Blue Ocean Invest and trust and fund services company Trident Trust Company Singapore were also penalised S$2.85 million, S$2.4 million and S$1.8 million respectively.
The penalties mark the conclusion of MAS's enforcement actions against financial institutions.
The 10 convicted money launderers were sentenced to jail terms of between 13 and 17 months in the nation's largest case of its kind. They were deported and barred from re-entering Singapore after completing their sentences.
The criminals held money gained from overseas scams and online gambling operations in bank accounts in Singapore, and converted some of their cash into real estate, cars, handbags and jewellery.
MAS said it has identified shortcomings in the financial institutions' customer risk assessments, their tracing of the sources of customers' wealth as well as their ability to monitor and follow up on suspicious transactions.
"The financial institutions have embarked on remediation of the deficiencies and MAS will monitor their progress closely," it said.
Four people were also issued prohibition orders preventing them from carrying out MAS-regulated activities.
In response to media queries, UOB said that it has implemented prompt remedial actions over the past two years and committed significant investments to enhance its internal risk management standards and capabilities further.
UBS, which agreed to take over Credit Suisse in March 2023, said that it acknowledged the findings and has cooperated fully with authorities to resolve the issue.
Blue Ocean Invest said that the company has fully cooperated with the authorities and has implemented measures to enhance internal policies and procedures.
A Trident Trust Company spokesperson also said it has cooperated with MAS's inspection and implemented a remediation plan to address breaches.
Citibank, UOB Kay Hian, Julius Baer and LGT Bank did not immediately respond to a request for comment.
In August last year, Singapore charged two ex-bankers from Citi and Julius Baer for forging loan and tax documents for the money launderers.
Singapore has also sought to make it easier for law enforcement to prosecute money laundering offences in the city-state.
In June 2024, the government identified Singapore's banking sector as posing the highest money laundering risk in the city-state.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
Rimini Street Awarded U.S. GSA Multiple Award Schedule (MAS) for Oracle, SAP and VMware Support and Security Services
LAS VEGAS--(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it has become an approved supplier on the United States General Services Administration's (GSA) Multiple Award Schedule (MAS) under the contract 47QTCA25D00DT. 'Rimini Street can help government agencies securely achieve cost and labor savings while enabling the investment of more funds into the latest technologies such as workflow, task automation and AI to improve operations, outcomes and citizen experiences.' Share The availability of Rimini Street on the GSA expedites federal, state, local and tribal government agencies' ability to select and switch from costly software vendor support to the Company's comprehensive support and advanced security services for Oracle, SAP and VMWare at up to a 50% discount compared to the software vendor's annual maintenance fees. To date, Rimini Street has helped clients save nearly $10 billion that they were able to use for both direct cost savings and funding new technology investments. A Proven, Better and Secure Enterprise Software Support Option Rimini Street offers ultra-responsive, premium support that includes support for application customizations at no additional charge and guarantees full support coverage on current software releases for up to 15 additional years from date of signing, with no required upgrades or migrations to new products or releases. Rimini Street also includes both a guaranteed 10-minute engineer response time and a four-hour resolution time for critical cases, 24/7/365. Rimini Street's more than 1,000 global engineers work as an extension of its clients' IT team to protect system uptime and ensure top performance from their software investments. Rimini Street support comes standard with exclusive security solutions that provide a secure extension of lifespan for Oracle, SAP and VMware products and releases - eliminating the need for disruptive, risky, and costly vendor-pressured upgrade, migration and re-platforming mandates just to remain on a fully supported platform. Rimini Street Continues to Serve as a Reliable Partner for Government Agencies 'Government agencies are on a mission to modernize IT, maximize labor productivity and reduce costs. Rimini Street has a strong track record of partnering with government agencies all over the world and across the U.S., including national security and military clients, to achieve this mission,' said Seth Ravin, CEO of Rimini Street. 'Rimini Street can help government agencies securely achieve cost and labor savings while enabling the investment of more funds into the latest technologies such as workflow, task automation and AI to improve operations, outcomes and citizen experiences.' Learn more about how Rimini Street empowers government agencies to achieve 'Transformation without Disruption™,' here. About Rimini Street, Inc. Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of end-to-end enterprise software support and innovation solutions and the leading third-party support provider for Oracle, SAP and VMware software. The Company offers a comprehensive portfolio of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize enterprise application, database, and technology software. The Company has signed thousands of contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who selected Rimini Street as their trusted, proven mission-critical enterprise software solutions provider and achieved better operational outcomes, realized billions of US dollars in savings and funded AI and other innovation investments. To learn more, please visit and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn. Forward-Looking Statements Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'anticipate,' 'assume,' 'believe,' 'continue,' 'could,' 'currently,' 'estimate,' 'expect,' 'forecast,' 'future,' 'intend,' 'may,' 'might,' 'outlook,' 'plan,' 'possible,' 'goal,' 'potential,' 'predict,' 'project,' 'seem,' 'seek,' 'should,' 'will,' 'would' or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street's business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, litigation, agreements and Court orders involving Oracle, the wind down of support services for Oracle's PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; changes in the business environment in which Rimini Street operates, including the impact of macro-economic trends, geopolitical tensions and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; the evolution of the enterprise software management and support landscape and our ability to attract and retain clients and further penetrate our client base; significant competition in the software support services industry and our intentions with respect to our pricing model; customer adoption of our expanded portfolio of products and services and products and services we expect to introduce; our expectations regarding new product offerings, partnerships and alliance programs, including but not limited to our partnership with ServiceNow; our ability to grow our revenue and accurately forecast revenue, along with the results of any efforts to manage costs to align with revenue expectations and expansion of our offerings; the expected impact of reductions in our workforce during the last and current fiscal year and associated reorganization costs; estimates of our total addressable market and expectations of client savings relative to use of other providers; variability of timing in our sales cycle; risks relating to retention rates, including our ability to accurately predict retention rates; the loss of one or more members of our management team; our ability to attract and retain additional qualified personnel; our business plan and ability to grow in the future and our ability to achieve and maintain profitability; the volatility of our stock price; our need and ability to raise equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; risks associated with global operations; our ability to prevent unauthorized access to our information technology systems and other cybersecurity threats; any deficiencies associated with generative artificial intelligence (AI) technologies potentially used by us or by our third-party vendors and service providers; our ability to protect the confidential information of our employees and clients and to comply with privacy regulations; our ability to maintain an effective system of internal control over financial reporting; our ability to maintain, protect and enhance our brand and intellectual property; changes in laws and regulations, including changes in tax laws or unfavorable outcomes of tax positions we take; tariff costs (including tariff relief or the ability to mitigate tariffs, in light of new or increased tariffs imposed by the United States government and the potential for retaliatory trade measures by affected countries); a failure by us to establish adequate tax reserves; adverse developments in and costs associated with defending pending litigation or any new litigation; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our ability to maintain our good standing with the United States government and international governments and capture new contracts with governmental entities; our credit facility's ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; uncertainty as to the long-term value of Rimini Street's equity securities; catastrophic events that disrupt our business or that of our clients; and those discussed under the heading 'Risk Factors' in Rimini Street's Quarterly Report on Form 10-Q filed on July 31, 2025, and as updated from time to time by Rimini Street's future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street's expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street's assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street's assessments as of any date subsequent to the date of this communication. © 2025 Rimini Street, Inc. All rights reserved. 'Rimini Street' is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
Business Wire
2 days ago
- Business Wire
Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer. ArteraAI Prostate is now recognized as an FDA-regulated Software as a Medical Device (SaMD). The technology's De Novo authorization establishes a new product code category for future AI-powered digital pathology risk-stratification tools, and enables its implementation at the point of diagnosis at qualified pathology labs in the U.S. This capability addresses a critical gap in prostate cancer care by reducing delays in delivering actionable insights at diagnosis, helping clinicians and patients make informed treatment decisions with greater confidence. 'This is a defining moment for AI in cancer care,' said Andre Esteva, CEO and co-founder of Artera. 'The FDA's decision validates the power of our MMAI platform to deliver on our vision to create AI-guided tools that enable data-backed and tailored treatments for each patient, leading to more confidence throughout the cancer journey, and ultimately, save more lives.' 'This approval highlights the groundswell of excitement surrounding the incorporation of AI into clinical practice flows. We need to utilize deep learning AI models to augment and better refine what a pathologist is able to report and Artera is leading the charge,' said Dr. Adam Cole, Founder and CSO at TruCore Pathology Group. 'As the demand for pathology services continues to outpace available capacity, tools like ArteraAI Prostate are critical. Implementing this software enhances our ability to deliver personalized insights more quickly, improves workflow efficiency, and allows us to scale services while increasing the quality of care.' Earning FDA De Novo authorization is a rare achievement, designed for novel medical innovations. This accomplishment marks yet another milestone for Artera, spotlighting its leadership and unwavering commitment to scientific rigor and excellence. Notably, the FDA authorization includes a Predetermined Change Control Plan, granting Artera the ability to expand platform capabilities through validating compatibility with additional digital pathology scanners without requiring further 510(k) submissions. The De Novo authorization for ArteraAI Prostate follows its earlier Breakthrough Device Designation. While the De Novo authorization applies specifically to the ArteraAI Prostate medical device software, Artera's underlying MMAI platform is also commercially available through the ArteraAI Prostate Test, as a Laboratory Developed Test (LDT). With this milestone, Artera continues to expand its pipeline of MMAI-powered software to support personalized cancer care. To learn more, visit About Artera Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera's MMAI platform leverages a patient's digitized biopsy images along with the patient's clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials, across different cancers, and is available in multiple versions across the globe. Artera's flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions. Additional MMAI-powered products include the ArteraAI Breast Test (UKCA), the ArteraAI Prostate Biopsy Assay (UKCA), and ArteraAI Prostate (FDA). Artera has regulatory authorization for its medical device product in the US and UK. Artera's headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit
Yahoo
3 days ago
- Yahoo
Paxos is applying to become a US bank — Here's why that matters
Paxos, the company that issues PayPal's $1 billion stablecoin, has applied for a national trust bank charter in the US, becoming the latest crypto company to pursue becoming a Federally-regulated bank in the US. It's a move that could give Paxos a gloss of establishment respectability, and a direct presence in America's financial sector. If approved, Paxos will be able to operate across the US without navigating the patchwork of local banking licences. However, while an approval would allow Paxos to hold customer assets and settle transactions, it won't act as a traditional lender that can accept deposits and issue loans. Paxos' charter application comes at a time when Washington, under the Trump administration, has warmed up to crypto. In July, President Donald Trump signed the Genius Act into law, effectively legalising stablecoins in the US. Circle and Ripple Paxos is the latest crypto company to pursue banking charter status. Circle and Ripple both applied earlier this summer. Chris Colson, payments guru at the Atlanta Federal Reserve, told DL News that an approval would enhance trust in their respective stablecoins. 'It potentially paves the way for broader institutional and cross-border adoption,' he said. Yet, those US banking charter ambitions rely on the hope that the regulatory thaw has extended to the US Treasury Department's Office of the Comptroller of the Currency, the agency that licenses and supervises all national banks. An OCC charter has been a tough nut to crack for crypto companies. Only one firm, Anchorage Digital, has been able to scale the process. Paxos itself tried to obtain a national bank charter in 2020 but its application stalled and expired in 2023. Earlier in August, the stablecoin issuer settled with the New York Department of Financial Services for $26.5 million over its alleged failure to conduct due diligence on Binance. Paxos was the issuer behind Binance's BUSD stablecoin, which once peaked at $23 billion in market value. Crypto market movers Bitcoin is down 1.4% over the past 24 hours and is trading at $118,433. Ethereum is up 2.6% in the same period to $4,295. What we're reading Trump Media brings Truth token plans into the open in latest SEC filing — DL News White House Crypto Advisor Bo Hines Steps Down — Unchained Do Kwon May Plead Guilty in US Case Over $40 Billion Terraform Collapse — Bloomberg Ether Breaks $4,000 as Spot ETFs Get Massive Inflows — Unchained Crypto law bonanza raises concerns around whether agency staff can regulate groundswell — DL News Osato Avan-Nomayo is our Nigeria-based DeFi correspondent. He covers DeFi and tech. Got a tip? Please contact him at osato@ — DL News Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
